Lipella Pharmaceuticals Inc. (LIPO): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
LIPO Stock Price Chart Interactive Chart >
LIPO Price/Volume Stats
| Current price | $2.55 | 52-week high | $7.72 |
| Prev. close | $2.36 | 52-week low | $1.72 |
| Day low | $2.15 | Volume | 421,700 |
| Day high | $2.63 | Avg. volume | 1,090,981 |
| 50-day MA | $2.47 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 5.86M |
Latest LIPO News From Around the Web
Below are the latest news stories about LIPELLA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LIPO as an investment opportunity.
Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological AssociationLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. |
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory BoardLipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |
Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for whi |
Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San FranciscoLipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced that Dr. Jonathan Kaufman, Co-Founder, Chairman, and CEO will be presenting at Biotech Showcase™ 2023. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41s |
LIPO Price Returns
| 1-mo | 8.05% |
| 3-mo | -36.09% |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.53% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...